A pharmaceutical innovation designed to treat diabetes is quietly dismantling the snacking industry. Not in five years. Not in three. Right now.
If you're a CMO at a confectionery brand, a snack food company, or a quick service restaurant, there's a reasonable chance you've discussed GLP-1 medications in passing. Perhaps you've seen the headlines about Ozempic and Wegovy. Maybe your finance team mentioned it during a volume decline post-mortem.
But have you actually quantified the impact on your category? Have you modelled what happens when a quarter of your addressable market fundamentally changes their relationship with food?
Because that's precisely what's happening. And the executives who haven't noticed are the ones whose categories will be disrupted most violently.
The Numbers Are Already Alarming
Kantar's latest UK data shows 4.1% of households now include someone taking GLP-1 medications, nearly doubling from 2.3% just twelve months earlier. That's not a trend line. That's an inflection point.
These aren't marginal behavioural shifts. They're fundamental rewirings of consumption patterns. GLP-1 users are reducing their grocery bills by 2.2 percentage points more than non-users, according to Kantar. The wallet share is moving elsewhere.
“85% of GLP-1 users report significant changes to their taste and appetite. They're not just eating less. They're wanting less.”
The US market, typically a leading indicator for UK trends, tells an even starker story. Goldman Sachs projects 70 million Americans could be taking GLP-1 medications by 2028. Today, 12.4% of US adults are already on these drugs, more than doubling from 5.8% in February 2024. Nearly a quarter of US households now have at least one GLP-1 user.
The Earnings Calls Tell the Real Story
If you want to understand how seriously CPG leadership is taking this threat, stop reading the press releases and start reading the earnings transcripts.
PepsiCo has reported five consecutive quarters of declining snack volumes. Mondelez posted a 4.1% net revenue drop in North America. Morgan Stanley has publicly identified Hershey as the most at-risk company among major packaged food manufacturers.
The category-level data is similarly troubling. Circana research shows chips and salty snacks are down 11.1% in households with GLP-1 users. A third of daily soda drinkers on GLP-1 medications have quit entirely. Fast-food spending falls approximately 8% following GLP-1 adoption.
- Confectionery: Net 66% of GLP-1 users eating less, Hershey flagged as most at-risk major CPG company
- Salty snacks: 11.1% volume decline in GLP-1 households, five quarters of PepsiCo decline
- Carbonated soft drinks: 33% of daily consumers on GLP-1s have quit entirely
- Quick service restaurants: 8% spending reduction post-adoption, 74% of UK users cutting takeaways
Sally Lyons Wyatt, Global EVP of Circana, captured the magnitude when she stated: "The rise of GLP-1 medications is a huge moment for the CPG industry." She projects that by 2030, 35% of all food and beverage sales will come from households with a GLP-1 user. That's not a niche. That's the new mainstream.
The Acceleration Is About to Get Faster
Everything above describes the current state. What happens next should concern you more.
In December 2025, regulators approved the oral version of Wegovy. The removal of injection barriers will dramatically accelerate adoption. The NHS already has 345,000 patients receiving weight-loss medications, with 4.1 million people in England currently eligible for Wegovy treatment.
GLP-1 patients typically experience a 20-30% reduction in calorie intake. When you compound that reduction across a third of your market, the volume implications are severe. People will still buy snacks - just far fewer of them, with fundamentally different preferences.
“GLP-1 will impact your category. The only variable is whether you respond before or after your competitors capture the repositioning opportunity.”
What Forward-Thinking Companies Are Doing
Not every executive is in denial. Some are moving decisively.
Nestle launched "Vital Pursuit" in 2024, their first entirely new brand in 30 years, specifically formulated for GLP-1 users. High protein, portion-controlled, nutrient-dense products designed around the altered appetite and nutritional needs of this growing consumer segment.
- New product development: Nestle's Vital Pursuit targets GLP-1 users directly with high-protein, portion-controlled formats
- Portfolio rebalancing: Shifting investment toward categories with lower GLP-1 impact (pet food, premium coffee, functional beverages)
- Reformulation: Increasing protein content and reducing portion sizes to align with changed consumption patterns
- Positioning pivot: Reframing snacks as 'functional nutrition' rather than indulgence occasions
Laurent Freixe, Nestle's CEO, was explicit about the rationale: "Weight management is a big opportunity." That framing matters. The companies treating GLP-1 as a threat to be weathered are playing defence. The companies treating it as a market to be captured are building competitive advantage.
The CMO's Urgent Agenda
If your brand sits in a vulnerable category, the time for scenario planning was two years ago. The time for action is now.
- Quantify your exposure: Model what happens to your category when 35% of purchases come from households consuming 20-30% fewer calories. Present that number to your board.
- Segment your portfolio: Identify which SKUs are most vulnerable (high-calorie indulgence, large formats, impulse occasions) versus which may benefit (protein-rich, functional, portion-controlled).
- Commission primary research: Understand how GLP-1 users in your category are changing behaviour. Generic industry data won't tell you what's happening to your specific consumers.
- Accelerate innovation: If Nestle can launch an entirely new brand targeting this segment, what's stopping you? The first-mover advantage in GLP-1-oriented products is still available.
- Revise your media strategy: If your advertising assumes a consumer who craves indulgence, you're speaking to a shrinking audience. How does your brand remain relevant to someone whose relationship with food has fundamentally changed?
The Executive Takeaway
Category disruption rarely announces itself with fanfare. It arrives quietly in pharmacies, in changed shopping baskets, in volume declines that get attributed to "promotional timing" or "competitive pressure" because the real cause is too uncomfortable to acknowledge.
“The executives who will navigate this disruption successfully are the ones who stopped asking 'Is this real?' and started asking 'How do we lead the response?'”
GLP-1 medications have already altered consumption patterns for millions of UK consumers. That number will grow substantially over the next three years as oral formulations remove adoption barriers and NHS eligibility expands. The snacking, confectionery, soft drinks, and QSR categories face structural headwinds that no amount of promotional activity will reverse.
Your category is already being disrupted. What matters now is whether you act before your competitors do.
Because in this market, the advantage goes to those who see clearly whilst others are still debating whether to look.